# Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia

> **NCT05549752** · PHASE3 · RECRUITING · sponsor: **Hippocration General Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Atrial Fibrillation Paroxysmal
- Coronary Artery Disease Without Residual Ischemia

## Interventions

- **DRUG:** Flecainide Injectable Solution
- **DRUG:** Amiodarone Injectable Solution

## Key facts

- **NCT ID:** NCT05549752
- **Lead sponsor:** Hippocration General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-24
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-01-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-06-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05549752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05549752, "Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05549752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*